-
ALSO READ
Metropolis Healthcare acquires Dr. Ganesan's Hitech Diagnostic Centre
Metropolis Healthcare slips as acquisition deal set to collapse
Board of Metropolis Healthcare approves scheme of merger
Board of Metropolis Healthcare approves appointment of director and interim compliance officer
Board of Metropolis Healthcare approves fund raise up to Rs 1500 cr
-
Metropolis Healthcare has completed the acquisition of Dr Ganesan's Hitech Diagnostic Centre (Hitech) along with its subsidiary Centralab Healthcare Services (Centralab) on Friday, 22 October 2021 for a cash consideration of Rs 636 crore.
The acquisition has been funded through internal accruals and debt of Rs 300 crore. Dr. Ganesan, the promoter and founder of Dr Ganesan's Hitech Diagnostic Centre (Hitech), will be part of the leadership team for next few years to enable a smooth transition and integration with Metropolis Healthcare. Metropolis Healthcare will also get access to 31 laboratories including 3 National Accreditation Board for Testing and Calibration Laboratories (NABL) and Indian Council of Medical Research (ICMR) accredited laboratories and 68 collection centres of Hitech. Post completion of the acquisition, Hitech and Centralab has become wholly-owned subsidiary and step down wholly owned subsidiary respectively of the company.
The acquisition of of Dr Ganesan's Hitech Diagnostic Centre (Hitech) along with its subsidiary Centralab Healthcare Services (Centralab) will help Metropolis Healthcare in - strengthening the leadership position, increase B2C contribution in focus cities, enable deeper penetration in mid-segment of the market and enhance profitability through revenue and cost synergies. On FY21, the revenue of Dr Ganesan's Hitech Diagnostic Centre (Hitech) stood at Rs 124 crore, rising 49% Y-o-Y. The business momentum also continued in FY22 with strong growth across all parameters, the press release highlighted.
Metropolis Healthcare's consolidated net profit surged to Rs 74.92 crore in Q1 FY22 from Rs 2.88 crore in Q1 FY21. Net sales surged 128.30% year-on-year (Y-o-Y) to Rs 326.76 crore during the quarter.
Shares of Metropolis Healthcare shed 1.12% to end at Rs 2,826.50 on Friday, 22 October 2021. Metropolis Healthcare is a leading diagnostics company in India with a widespread presence across 19 states in India.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU